Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients with non-small-cell lung cancer and gastric cancer in China. In this study, we determined the effect of apatinib on the interaction of specific antineoplastic compounds with P-glycoprotein (ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2). Our results showed that apatinib significantly enhanced the cytotoxicity of ABCB1 or ABCG2 substrate drugs in KBv200, MCF-7/adr, and HEK293/ABCB1 cells overexpressing ABCB1 and in S1-M1-80, MCF-7/FLV1000, and HEK293/ABCG2-R2 cells overexpressing ABCG2 (wild-type). In contrast, apatinib did not alter the cytotoxicity of specific substrates in the parental cells and cells overexpressing ABCC1. Apatinib significantly increased the intracellular accumulation of rhodamine 123 and doxorubicin in the multidrug resistance (MDR) cells. Furthermore, apatinib significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner. The ATPase activity of both ABCB1 and ABCG2 was significantly increased by apatinib. However, apatinib, at a concentration that produced a reversal of MDR, did not significantly alter the ABCB1 or ABCG2 protein or mRNA expression levels or the phosphorylation of AKT and extracellular signal-regulated kinase 1/2 (ERK1/2). Importantly, apatinib significantly enhanced the effect of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice. In conclusion, apatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression. Apatinib may be useful in circumventing MDR to other conventional antineoplastic drugs.

[1]  Zhe-Sheng Chen,et al.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.

[2]  Zhe-Sheng Chen,et al.  Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. , 2009, Cancer letters.

[3]  Fang Wang,et al.  Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function , 2009, PloS one.

[4]  F. Wang,et al.  Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function , 2009, Cancer Chemotherapy and Pharmacology.

[5]  Suneet Shukla,et al.  Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.

[6]  Liwu Fu,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914)) , 2008 .

[7]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[8]  T. Fojo,et al.  Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). , 2008, Biochemical pharmacology.

[9]  G. Jansen,et al.  Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors , 2008 .

[10]  Antony W Burgess,et al.  EGFR family: Structure physiology signalling and therapeutic targets† , 2008, Growth factors.

[11]  V. Leblanc,et al.  Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol , 2008, Apoptosis.

[12]  S. Bates,et al.  Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.

[13]  L. Lou,et al.  ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein , 2007, British Journal of Cancer.

[14]  Yong-cheng Lin,et al.  Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway , 2007, Cancer biology & therapy.

[15]  W. Berdel,et al.  Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. , 2007, Current drug targets.

[16]  R. Herbst,et al.  Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[17]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[18]  R. Pérez-Tomás,et al.  Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.

[19]  T. Ozben.  Mechanisms and strategies to overcome multiple drug resistance in cancer , 2006, FEBS letters.

[20]  Y. Yeom,et al.  ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. , 2006, Experimental cell research.

[21]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[22]  M. Shibuya.  Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. , 2006, Endothelium : journal of endothelial cell research.

[23]  Zhe-Sheng Chen,et al.  Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo , 2006, Cancer biology & therapy.

[24]  A. Kong,et al.  Modulation of nuclear factor E2-related factor 2–mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin , 2006, Molecular Cancer Therapeutics.

[25]  R. Roskoski.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[26]  S. Kohno,et al.  Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. , 2005, Lung cancer.

[27]  G. Kéri,et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.

[28]  Balázs Sarkadi,et al.  Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. , 2005, Biochimica et biophysica acta.

[29]  C. Choi,et al.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal , 2005, Cancer Cell International.

[30]  L. Fu,et al.  Reversal of P‐gp mediated multidrug resistance in‐vitro and in‐vivo by FG020318 , 2004, The Journal of pharmacy and pharmacology.

[31]  L. Fu,et al.  Screening novel, potent multidrug-resistant modulators from imidazole derivatives. , 2004, Oncology research.

[32]  L. Fu,et al.  Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance , 2004, Cancer Chemotherapy and Pharmacology.

[33]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[34]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[35]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[36]  P. Dennis,et al.  Activation of the PI3K/Akt pathway and chemotherapeutic resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  J. Schuetz,et al.  Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Ambudkar,et al.  Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). , 2002, Biochemistry.

[39]  G. Kéri,et al.  Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. , 2002, Biochimica et biophysica acta.

[40]  K. Linton,et al.  Repacking of the transmembrane domains of P‐glycoprotein during the transport ATPase cycle , 2001, The EMBO journal.

[41]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[42]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[43]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[44]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[46]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[47]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[48]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[49]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[51]  S. Ambudkar.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.

[52]  K. Ueda,et al.  Anti‐cancer drugs and glutathione stimulate vanadate‐induced trapping of nucleotide in multidrug resistance‐associated protein (MRP) , 1997, FEBS letters.

[53]  S. Tseng,et al.  A comparison of the parameter estimating procedures for the Michaelis-Menten model. , 1990, Journal of theoretical biology.

[54]  J V Watson,et al.  Improved methodology for intracellular enzyme reaction and inhibition kinetics by flow cytometry. , 1987, Cytometry.

[55]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[56]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.